varespladib methyl

Varespladib methyl is an oral phospholipase A2 inhibitor that was initially developed for treating acute coronary syndrome and other inflammatory conditions. It functions as a prodrug that is rapidly metabolized to varespladib, its active form. ## Pharmacology and Mechanism of Action Varespladib methyl acts by inhibiting secretory phospholipase A2 (sPLA2) enzymes, particularly the IIa, V, and X isoforms. This inhibition disrupts the first step of the arachidonic acid pathway of inflammation[4]. The drug demonstrates potent inhibition of phospholipase activity at nanomolar and picomolar IC50 levels[3]. ## Development History and Clinical Applications Originally investigated for cardiovascular conditions, varespladib methyl showed promise in reducing LDL-cholesterol levels in patients with coronary artery disease[4]. Phase II clinical trials revealed that the drug was well tolerated, though it didn't demonstrate good efficacy for rheumatoid arthritis, asthma, and ulcerative colitis[4]. More recently, varespladib methyl has been studied as a potential treatment for snakebite envenoming. It's being evaluated for its ability to inhibit venom sPLA2s, which are nearly ubiquitous components of snake venoms[6]. A phase II clinical trial conducted in India and the USA assessed its efficacy and safety in patients bitten by venomous snakes, with all patients receiving standard care including antivenom[6]. ## Formulation and Dosing For snakebite envenoming studies, varespladib methyl is presented as a 250 mg tablet with an initial dose of 500 mg, followed by 250 mg doses[3]. In clinical trials for acute coronary syndrome, the drug was administered orally twice daily for one week[6]. ## Chemical Properties Varespladib methyl (C22H22N2O5) is a methyl ester resulting from the formal condensation of the carboxy group of varespladib with methanol. It has a molecular weight of 394.4 g/mol[2].

Other names

Varespladib methyl estermethyl ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetatemethyl 2-((1-benzyl-3-(carbamoylcarbonyl)-2-ethyl-1H-indol-4-yl)oxy)acetate